Hypoparathyroidism Pipeline Review, H1 2018 with Analysis on Drug Profiles, Dormant Projects and Product Development Milestones - ResearchAndMarkets.com

DUBLIN--()--The "Hypoparathyroidism - Pipeline Review, H1 2018" report has been added to ResearchAndMarkets.com's offering.

The pipeline guide provides a snapshot of the global therapeutic landscape of Hypoparathyroidism (Hormonal Disorders).

The pipeline guide reviews pipeline therapeutics for Hypoparathyroidism (Hormonal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Hypoparathyroidism (Hormonal Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Hypoparathyroidism (Hormonal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Hypoparathyroidism (Hormonal Disorders).

Companies Mentioned

  • Ascendis Pharma A/S
  • Chugai Pharmaceutical Co Ltd
  • Eli Lilly and Co
  • Entera Bio Ltd
  • GC Pharma
  • Shire Plc

Key Topics Covered

  1. Introduction
  2. Report Coverage
  3. Hypoparathyroidism - Overview
  4. Hypoparathyroidism - Therapeutics Development
  5. Pipeline Overview
  6. Pipeline by Companies
  7. Products under Development by Companies
  8. Hypoparathyroidism - Therapeutics Assessment
  9. Assessment by Target
  10. Assessment by Mechanism of Action
  11. Assessment by Route of Administration
  12. Assessment by Molecule Type
  13. Hypoparathyroidism - Companies Involved in Therapeutics Development
  14. Hypoparathyroidism - Drug Profiles
  15. Hypoparathyroidism - Dormant Projects
  16. Hypoparathyroidism - Product Development Milestones
  17. Featured News & Press Releases

For more information about this report visit https://www.researchandmarkets.com/research/fctbjl/hypoparathyroidism?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Endocrine and Metabolic Disorders Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Endocrine and Metabolic Disorders Drugs